Biofil Chemicals & Pharmaceuticals Limited — Important, 11-02-2025: Financial Result Updates

**Biofil Chemicals and Pharmaceuticals Limited Financial Summary**

Consolidated financial results reveal a revenue of ₹1,419.52 crore for the quarter, marking a substantial increase over previous periods. The year-over-year revenue growth stands at approximately 14.4%, driven primarily by an uptick in demand in the Pharma division and improved operational execution.

Net profit for the quarter was reported at ₹16.46 crore, showing a sharp increase compared to ₹9.33 crore from the same quarter last year. The Earnings Per Share (EPS) for the quarter stands at ₹0.10, reflecting improved profitability influenced by cost control measures and a reduction in operational inefficiencies.

Operational costs saw a modest increase of approximately 6.5%, primarily due to fluctuations in material prices and a slight rise in employee expenses. However, effective cost management strategies have mitigated their impact on the overall profitability.

The balance sheet reflects a solid financial foundation, with total assets of ₹4,518.98 crore and total liabilities at ₹2,662.88 crore, indicating a healthy debt-to-equity ratio. Cash flow dynamics remain stable, supporting ongoing operations and potential investments.

Strategically, the company is focusing on harnessing growth opportunities in its key segments, especially in pharmaceuticals, while continuing to streamline operational efficiencies.

For investors, given the company's promising financial performance and strategic position, a hold position seems prudent while monitoring developments in market demand and cost efficiency improvements.